ArticleMolecular cancer2025
C1Q
Abstract read
In one paragraph
Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- KMT5a-Mediated IRF3 Stabilization Enhances Macrophage Chemotaxis and Renal Fibrosis Progression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- SETD8-mediated mono-methylation of YAP at K76 promotes K48-linked polyubiquitination and degradation to suppress colorectal cancer.Cell death and differentiation · 2026Article
- Upregulation of macrophage UPP1 promotes lung adenocarcinoma metastasis through an mtROS-cGAS-NLRP3 inflammasome axis.Cell death discovery · 2026Article
- SETD8 promotes ovarian clear cell carcinoma by epigenetically activating RNA metabolism genes via H4K20me1.Scientific reports · 2026Article
- The lysine methyltransferase KMT5a and p53 regulate the expression of the key autophagy adaptor p62/SQSTM1 in glioblastoma.Cell communication and signaling : CCS · 2026Article
- Plant-Derived Bioactive Compounds in Inflammation-Related Cancers: Mechanisms and Therapeutic Potential.Plants (Basel, Switzerland) · 2026Review
- Review
- Article
- The emerging paradigms of SETD family enzymes as epigenetic regulators of the immune response in inflammatory diseases.Frontiers in immunology · 2026Review
- A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.Frontiers in immunology · 2026Article
- Single-Cell and Multi-Omics-Based Characterization of Gastric Cancer Identifies TPP1 as a Potential Target for Gastric Cancer Progression and Treatment.Oncology research · 2026Article
- Integrative single-cell and spatial transcriptomic analysis reveals lipid metabolism-mediated macrophage heterogeneity during colorectal cancer liver metastasis progression.Journal of translational medicine · 2025Article
- Tumor-associated macrophages in cancer: from mechanisms to application.Molecular biomedicine · 2025Review
- Immunoregulatory roles of post-translational modifications in colorectal cancer: mechanisms and therapeutic implications.Cellular and molecular life sciences : CMLS · 2025Review
- CLL, together with C1qR, suppresses WSSV infection by regulating the activation of Dorsal.Journal of virology · 2025Article
- Lignin Nanoparticles from Coffee Grounds Enhance the Cytotoxicity of Coffee Grounds Lignin and Induce Apoptosis in Colorectal Cancer (CRC) Cell Lines.Nanomaterials (Basel, Switzerland) · 2025Article
- Multiple functions of the lysine methyltransferase KMT5a in cancer: potential targets for innovative therapies.Clinical epigenetics · 2025Review
- Innate immunity in tumors: roles and therapeutic targets.Frontiers in immunology · 2025Review
- Editorial: Epigenetics and stem cell therapy in cancer and diseases.Frontiers in molecular medicine · 2025Article
- Single-cell and spatial transcriptomics integration reveals FAM49B promotes tumor-associated macrophages polarization in colorectal cancer via the MK pathway.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Veronica Veschi *Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90127, Italy. veronica.veschi@uniroma1.it.
Francesco Verona *Department of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Sebastiano Di BellaDepartment of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90127, Italy.
Alice TurdoDepartment of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Miriam GaggianesiDepartment of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90127, Italy.
Simone Di FrancoDepartment of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90127, Italy.
Laura Rosa MangiapaneDepartment of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Chiara ModicaDepartment of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90127, Italy.
Melania Lo IaconoDepartment of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Paola BiancaDepartment of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Ornella Roberta BrancatoDepartment of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90127, Italy.
Caterina D'AccardoDepartment of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Gaetana PorcelliDepartment of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Vincenzo Luca LentiniVilla Sofia-Cervello Hospital, Palermo, 90146, Italy.
Isabella SperdutiClinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS - Regina Elena National Cancer Institute, Rome, 00144, Italy.
Elisabetta SciaccaCentre for Experimental Medicine and Rheumatology, the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, Bartsand, London, UK.
Peter FitzgeraldGenome Analysis Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
David Lopez-PerezChemical Immunology Section, Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD, USA.
Pierre MartineChemical Immunology Section, Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD, USA.
Kate BrownChemical Immunology Section, Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD, USA.
Giuseppe GianniniDepartment of Molecular Medicine, University of Rome La Sapienza, Rome, 00161, Italy.
Ettore AppellaChemical Immunology Section, Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD, USA.
Giorgio Stassi *Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, 90127, Italy. giorgio.stassi@unipa.it.
Matilde Todaro *Department of Health Promotion Sciences, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy.
Funding
Center for Cancer Research, NCI, NIH Intramural GrantFondazione AIRC per la ricerca sul cancro ETS AIRC IG (21445)Fondazione AIRC per la ricerca sul cancro ETS AIRC IG (24329)Fondazione AIRC per la ricerca sul cancro ETS AIRC IG (30306)Ministero della Salute PNRR-MAD-2022-12376835Ministero della Salute PSN2015, 6.2, CUP176J17000470001Ministero dell'Istruzione, dell'Università e della Ricerca Dipartimenti di Eccellenza - L. 232/2016Ministero dell'Università e della Ricerca FESR FSE PON Ricerca e Innovazione 2014-2020 DM 1062/2021Ministero dell'Università e della Ricerca PNRR - M4C2-l1.3 Project PE00000019 'HEAL ITALIA' CUP B53C22004000006Ministero dell'Università e della Ricerca PNRR - M4C2-l1.3 Project PE00000019 'HEAL ITALIA' CUP B73C22001250006
Abstract
backgroundIn many tumors, the tumor suppressor TP53 is not mutated, but functionally inactivated. However, mechanisms underlying p53 functional inactivation remain poorly understood. SETD8 is the sole enzyme known to mono-methylate p53 on lysine 382 (p53
methodsWe analyzed SETD8 and p53
resultsBy integrating bulk RNAseq and scRNAseq approaches in CRC patients, SETD8-mediated p53 regulation resulted the most significantly enriched pathway. p53
conclusionsThese findings suggest that p53
Indexed as
Colonic NeoplasmsHistone-Lysine N-MethyltransferaseMacrophagesTumor Suppressor Protein p53AnimalsCell Line, TumorDisease ProgressionDNA MethylationGene Expression Regulation, NeoplasticHumansMiceNeoplastic Stem CellsTripeptidyl-Peptidase 1Tumor-Associated MacrophagesHistone-Lysine N-MethyltransferaseKMT5A protein, humanTP53 protein, humanTpp1 protein, ratTripeptidyl-Peptidase 1Tumor Suppressor Protein p53C1Q+ TPP1+ macrophagesCancer stem cellsCRCIBDP53K382me1SETD8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.